Pemetrexed combination therapy in the treatment of non-small cell lung cancer

Seminars in Oncology

Volumn 29, Issue 2 SUPPL. 5, 2002, Pages 23-29

  Rosell, Rafael ^a,b   Crinó, Lucio ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b BELLARIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CHLORMETHINE; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PEMETREXED;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

EID: 0036258047     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(02)70212-1     Document Type: Review

References (44)

1. Discodermolide: Just another microtubule-stabilizing agent? No! A lesson in synergy
2. Taxol and other microtubule-interactive agents
3. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience
4. The use of the nitrogen mustards in the palliative treatment of carcinomas. With particular reference to bronchogenic carcinoma
5. Continuous-infusion cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer
6. Multimodality treatment of non-small cell lung cancer: Response to cisplatin, VP-16, and 5-FU chemotherapy and to surgery and radiation therapy
7. Cyclophosphamide and ifosfamide combination as neoadjuvant chemotherapy for locally advanced non-small cell lung cancer: A meta-analytic review
8. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: A preliminary report from the Okayama Lung Cancer Study Group
9. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma
10. LY231514, a pyrrolo [2,3-d] pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes
11. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor of primary tumor response and overall survival
12. Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma
13. Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase
14. Overview of phase I trials of multitargeted antifolate (MTA, LY231514)
15. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomized trials
16. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study
17. Phase II study of LY231514 in patients with advanced non-small cell lung cancer (NSCLC)
18. Overview of MTA in the treatment of non-small cell lung cancer
19. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer
20. Interactions between the multitargeted antifolate (MTA, LY231514) and cisplatin in non-small cell lung cancer (NSCLC) cell lines
21. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin
22. LY231514 (MTA): Relationship of vitamin metabolite profile to toxicity
23. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, permetrexed disodium, ALIMTA) and cisplatin: A multicenter phase II trial
24. Cisplatingemcitabine combination in advanced non-small-cell lung cancer: A phase II study
25. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project
26. Chemotherapy of advanced non-small-cell lung cancer: A comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.)
27. Phase Il study of MTA (Alimta) and cisplatin in patients with advanced non-small cell lung cancer (NSCLC)
28. Low thymidylate synthase and ERCCI gene expressions are associated with increased survival after neoadjuvant 5-FU/cisplatin/radiotherapy for esophageal adenocarcinoma
29. Messenger RNA levels of XPAC and ERCCI in ovarian cancer tissue correlate with response to platinum-based chemotherapy
30. A phase I trial of MTA and gemcitabine in patients with locally advanced or metastatic cancer
31. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors
32. Beta-tubulin mutations in circulating extracellular DNA of non-small cell lung cancer (NSCLC) patients (Pts)
33. A common pharmacophore for epothilones and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells
34. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations
35. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) in colorectal cancer cells and xenograft model is overcome by inhibition of nuclear factorkappa B activation
36. Clinical and pharmacokinetic phase I study of MTA (multi-targeted antifolate, LY231514) and paclitaxel (P) in patients with solid tumors administered every 21 days
37. Alimta in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in a phase I trial
38. A phase I study of the multitargeted antifolate ALIMTA in combination with oxaliplatin (LOHP) in metastatic solid tumors
39. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC)
40. Allele loss in chromosome 11p15.5 predicts survival of patients with stage I lung cancer
41. Association of chromosome 11 locus D11S12 with histology, stage and metastases in lung cancer
42. Tumour site, sex, and survival in colorectal cancer
43. Improved therapeutic index by leucovorin of edatrexate, cyclophosphamide, and cisplatin regimen for non-small-cell lung cancer
44. Plasma homocysteine levels and mortality in patients with coronary artery disease